The Network Pharmacology Company
e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.
e-Therapeutics is listed on AIM with the ticker symbol ETX
Progress in ETS2101 Phase Ib Study
e-Therapeutics has announced that the first patient has been enrolled into its phase 1b programme for its cancer drug, ETS2101. More details available here.
Full year results
e-Therapeutics annual report and accounts for the year ended 31 January 2015 has been released. It can be viewed here.
e-Therapeutics' Impact is rated World Class
The impact of e-Therapeutics plc (AIM: ETX) drug discovery activities has been rated World Class by the UK's National Research and Impact Assessment exercise. More details available here.